GlaxoSmithKline (Netherlands)

Recent papers from GlaxoSmithKline (Netherlands)

1. Vaccine Ligand Binding Assay DevelopmentBioanalysis · 2026
2. PyMolGen: Database-Driven Molecular Generation of Drug-Like CompoundsJournal of Chemical Information and Modeling · 2026
3. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial2022
4. Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasetsEuropean Respiratory Journal · 2026
5. Fully Automatable Relative Binding Free Energy Calculations with Enhanced Sampling using FAST/MBAR2026
6. Vaccine Ligand Binding Assay Life Cycle Management, Assay Maintenance, Monitoring and TransferBioanalysis · 2026
7. Paleolatitude.org 3.0: A calculator for paleoclimate and paleobiology studies based on a new global paleogeography model.2026
8. Vaccine efficacy estimands and power considerationsStatistical Methods in Medical Research · 2026
9. Disordered bile acid metabolism in alcohol-related hepatitis2026
10. 2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates ( PART 1A – Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing & Reporting PART 1B – Regulatory Agencies’ Input on Regulated Bioanalysis/BMV)Bioanalysis · 2026
11. 2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A – Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B – Regulatory Agencies’ Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))Bioanalysis · 2026
12. P-768. Clinical Complications Among Patients with Complicated Urinary Tract Infections Treated with Intravenous Carbapenems in Hospital: a US Cohort StudyOpen Forum Infectious Diseases · 2026
13. P-786. Comparison of Length of Stay and Hospitalization Costs Among Patients with Complicated Urinary Tract Infection including Acute Pyelonephritis by Antibiotic Hospital Discharge Treatment StrategyOpen Forum Infectious Diseases · 2026
14. Exchange Time From Time-Dependent Diffusion-Weighted Mri as a Potential Biomarker for Treatment Response in Human Brain MetastasisNeuro-Oncology · 2025
15. DNA methylation associations with cognitive function in early-stage hormone receptor-positive breast cancer patientsEpigenomics · 2025
16. A multifunctional anti-O-Antigen human monoclonal antibody protects against Shigella sonnei infection in vivoProceedings of the National Academy of Sciences · 2025
17. Pulmonary macrophage subsets display distinct metabolic responses to polarising stimuli in vivo2025
18. Current diagnostic and therapeutic management of chronic rhinosinusitis with nasal polyps in Austria: insights and unmet needs from a nationwide surveyScientific Reports · 2025
19. Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stabilitymAbs · 2025
20. Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in MedicinesOrganic Process Research & Development · 2025